Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

Figure 2 Liver type I collagen content. A: Immunohistochemical staining of liver tissue from control (Con), fibrotic (CCl₄), rosiglitazone (Rosi), serelaxin (Rln) or combination-treated (Rosi + Rln) mice. Bar: 100 μm; B: Type I collagen staining quantified; C: Type I collagen gene expression determined by qPCR. Data are expressed as mean ± SE, and analyzed by ANOVA (n = 5). ^aP < 0.05 vs Con; ^bP < 0.05 vs CCl₄, Rosi, or Rln.